April 16, 2025; Boise, IDAHO — The Fatty Liver Foundation (FLF) today announces the launch of the fourth annual "The State of Steatotic (Fatty) Liver Care in America: Patient Perspectives Research", a nationwide survey designed to capture the lived experiences of individuals affected by metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated steatotic liver disease (MASLD), and alcohol-associated forms of steatotic liver disease.

Fatty Liver Foundation Supports Biden-Harris Administration Proposal to Expand Coverage for Anti-Obesity Medications

November 26, 2024; Boise, IDAHO —Today, the Fatty Liver Foundation (FLF) applauds the Biden-Harris Administration for proposing a landmark rule to expand Medicare and Medicaid coverage for anti-obesity medications (AOMs). This bold step acknowledges obesity as a chronic disease and aims to provide millions of Americans with access to life-changing treatments that improve health outcomes and reduce healthcare costs.

Fatty Liver Foundation to Present New Findings Expanding Understanding of Steatotic Liver Disease Patient Experiences at AASLD The Liver Meeting® 2024

November 7, 2024; Boise, IDAHO — The Fatty Liver Foundation (FLF) will present new insights into the evolving experiences of individuals with Steatotic Liver Disease (SLD), including Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Metabolic Dysfunction-Associated Steatohepatitis (MASH), and Alcohol-Associated Liver Disease (ALD), at this year’s The American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® (TLM), held from November 15-19 in San Diego, California. The poster presentation, titled "Evolution of MASLD/MASH Patient Experiences: Insights from ‘The State of Steatotic (Fatty) Liver Care in America’ Surveys 2022-2024" (Abstract Number: 2299), provides a comprehensive look at patient-reported challenges, access to care, and progress in SLD management across the U.S.

FATTY LIVER FOUNDATION MOURNS THE LOSS OF DR. STEPHEN HARRISON, A VISIONARY IN HEPATOLOGY

April 25, 2024; Boise, IDAHO —With profound grief, the Fatty Liver Foundation (FLF) marks the passing of Dr. Stephen Harrison on Tuesday, April 23, a monumental figure in hepatology whose passion and innovation have left an indelible mark on the field.

FATTY LIVER FOUNDATION MARKS WORLD LIVER DAY WITH LAUNCH OF ITS ANNUAL U.S. PATIENT SURVEY AMID BREAKTHROUGH THERAPIES

FLF unveils the third-year launch of “The Steatotic (Fatty) Liver Care in America: Patient Perspectives Research,” a pioneering nationwide initiative that empowers MAFLD/MASH patients to share their experiences and drive ongoing improvements in patient care

April 19, 2024; Boise, IDAHO — In observance of World Liver Day, the Fatty Liver Foundation (FLF) proudly announces the launch of this year’s "The State of Steatotic (Fatty) Liver Care in America: Patient Perspectives Research." This pivotal, nationwide survey comes at a transformative time with the introduction of Rezdiffra™, the first FDA-approved treatment in the U.S. for adults with metabolic dysfunction-associated steatohepatitis (MASH) who have moderate to advanced liver fibrosis, used in conjunction with diet and exercise.

A New Dawn in Liver Health: Fatty Liver Foundation Applauds Breakthrough FDA Approval of REZDIFFRA™ (resmetirom) for MASH Treatment

BOISE, ID – MARCH 14, 2024 – The Fatty Liver Foundation (FLF) heralds a significant milestone in the field of liver health with the U.S. Food and Drug Administration’s (FDA) approval of REZDIFFRA™ (resmetirom), developed by Madrigal Pharmaceuticals, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). This landmark approval paves the way for the first-ever medication for adults with fibrosis stage 2 or 3 due to MASH, marking a watershed moment in the pursuit of effective treatments. REZDIFFRA™ has been recognized by the FDA through breakthrough therapy and priority review designations for this crucial indication.

FLF and Sober Liver Embark on a Collaborative Mission to Revolutionize Liver Health Support and Advocate for Patients Nationwide

BOISE, ID & AURORA, CO / NOVEMBER, 28, 2023 – In a major step forward for liver health, the Fatty Liver Foundation (FLF) and the Society for Sober Liver Survival (Sober Liver) are pleased to announce their formal collaboration through a Memorandum of Understanding (MOU). This collaboration unites the two organizations in the fight against liver diseases, especially Metabolic and Alcohol-Associated Liver Disease (MetALD), a condition that has gained increased recognition in the medical community following a recent change in disease nomenclature by hepatology experts in June 2023.

Bridging the Awareness Gap: Step Up for NASH

June 8, 2023; Boise, IDAHO ─ The Fatty Liver Foundation (FLF), a leading patient advocacy organization championing liver health in the United States, invites Americans to participate in marking International NASH Day on Thursday, June 8^th. This significant day is devoted to enhancing awareness about non-alcoholic fatty liver disease (NAFLD) and its severe form, non-alcoholic steatohepatitis (NASH). By shining a spotlight on these conditions, FLF aims to inspire early detection, prevention, and effective treatment strategies, all in a bid to ultimately improve patient outcomes.

FLF and SAIL are stepping up to NASH by developing a risk stratification tool with a 77% detection rate for NAFLD.

CAMBRIDGE, MA & BOISE, ID / ACCESSWIRE / JUNE, 8, 2023 - The Fatty Liver Foundation (FLF), a leading patient advocacy organization, today announced the development of its AI Fatty Liver Risk Stratification Tool, in conjunction with a collaborative health data research software provider Secure AI Labs (SAIL).

Cerrando la brecha de concientización para tomar medidas para la Salud del Hígado

8 de Junio, 2023; Boise, IDAHO ─ The Fatty Liver Foundation (FLF), una organización líder en la defensa de los pacientes  con enfermedades hepáticas  en los Estados Unidos, invita a todos los estadounidenses a celebrar este 8 de Junio como el Día Internacional de la Enfermedad de Hígado Graso No Alcohólico (EHGNA) y la Esteatohepatitis No Alcohólica (EHNA), Destacando estas condiciones, la FLF tiene como objetivo inspirar estrategias de detección temprana, prevención y tratamiento efectivo, todo en un esfuerzo por mejorar los estándares de la salud de los pacientes.